2158362-38-8

2158362-38-8 structure

Name: Neihulizumab
Chemical Name: Neihulizumab
CAS Number: 2158362-38-8
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2023-01-13 13:28:44
Modify Date: 2024-01-27 20:43:09
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1].

Name	Neihulizumab

Description	Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Inflammation/Immunology
In Vitro	Neihulizumab 是一种针对 P-选择素糖蛋白配体-1 (PSGL-1) 的单克隆抗体。Neihulizumab 与人 PSGL-1 结合，从而优先诱导晚期活化 T 细胞的凋亡。在炎症部位，血管内皮表达 P-选择素，活化的 T 细胞与这些部位结合并通过 PSGL-1 的表达迁移。以这种方式，Neihulizumab 被认为靶向活化的 T 细胞并抑制运输到发炎组织部位[1]。
References	[1]. Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557. [2]. Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497.

No Any Chemical & Physical Properties